Talk:Covaxin

This is the talk page for discussing improvements to the Covaxin article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

The contentious topics procedure applies to this page. This page is related to COVID-19, broadly construed, which has been designated as a contentious topic.

Editors who repeatedly or seriously fail to adhere to the purpose of Wikipedia, any expected standards of behaviour, or any normal editorial process may be blocked or restricted by an administrator. Editors are advised to familiarise themselves with the contentious topics procedures before editing this page.

This article is written in Indian English, which has its own spelling conventions (colour, travelled, centre, analysed, defence) and some terms that are used in it may be different or absent from other varieties of English. According to the relevant style guide, this should not be changed without broad consensus.

This article is rated C-class on Wikipedia's content assessment scale.
It is of interest to the following WikiProjects:

COVID-19 Mid‑importance

	COVID-19 portal This article is within the scope of WikiProject COVID-19, a project to coordinate efforts to improve all COVID-19-related articles. If you would like to help, you are invited to join and to participate in project discussions.COVID-19Wikipedia:WikiProject COVID-19Template:WikiProject COVID-19COVID-19 articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

India Mid‑importance

	India portal This article is within the scope of WikiProject India, which aims to improve Wikipedia's coverage of India-related topics. If you would like to participate, please visit the project page.IndiaWikipedia:WikiProject IndiaTemplate:WikiProject IndiaIndia articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

It is requested that a biochemistry diagram or diagrams be included in this article to improve its quality. Specific illustrations, plots or diagrams can be requested at the Graphic Lab.
For more information, refer to discussion on this page and/or the listing at Wikipedia:Requested images.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Covaxin.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Daily pageviews of this article

A graph should have been displayed here but graphs are temporarily disabled. Until they are enabled again, visit the interactive graph at pageviews.wmcloud.org

Requested move 9 May 2021[edit]

The following is a closed discussion of a requested move. Please do not modify it. Subsequent comments should be made in a new section on the talk page. Editors desiring to contest the closing decision should consider a move review after discussing it on the closer's talk page. No further edits should be made to this discussion.

The result of the move request was: page moved. Murtaza.aliakbar (talk) 09:23, 16 May 2021 (UTC)[reply]

BBV152 → Covaxin – As per WP:COMMONNAME. Bharat Biotech, the developing company markets it as COVAXIN. They are developing another vaccine, but that's not named commercially, so it's BBV154 only. Whereas, COVAXIN case is the opposite, bharatbiotech.com Saha ❯❯❯ Stay safe 18:08, 9 May 2021 (UTC)[reply]

Edit to the move request, BBV152 → Covaxin. Saha ❯❯❯ Stay safe 05:30, 10 May 2021 (UTC)[reply]

Note: I have modified the request per above. Run n Fly (talk) 17:10, 10 May 2021 (UTC)[reply]

Support and move to Covaxin as COVAXIN is not an abbreviation. Thus, capitalization is unnecessary per MOS:ABBR. Run n Fly (talk) 19:33, 9 May 2021 (UTC)[reply]
Support move to Covaxin per WP MOS In ictu oculi (talk) 20:35, 9 May 2021 (UTC)[reply]
Move to Covaxin per MOS:CAPS. The vaccines usually doesn't have a acronym or capitalization. 110.137.161.129 (talk) 20:53, 9 May 2021 (UTC)[reply]
Support Covaxin (not all caps) per the above. While the "technical names" were good early on, we now have common names for many of these vaccines and should consider moving all of them for which a common name has arisen - keeping in mind that in some cases it may be the trade name (as it is here), and in others it may not (as in Pfizer-BioNTech). -bɜ:ʳkənhɪmez (User/say hi!) 00:24, 10 May 2021 (UTC)[reply]
support per above editors--Ozzie10aaaa (talk) 11:46, 10 May 2021 (UTC)[reply]
Support Unlike other COVID-19 vaccines, which are usually known by their manufacturer's name (ex. Pfizer/Astra-Zeneca/J&J [COVID-19] vaccine) and have various other names which are not as well known (Covishield may be an exception, but that is India only), this one is usually called "Covaxin" in Indian media (and probably in the media of other countries too now). MSG17 (talk) 14:52, 10 May 2021 (UTC)[reply]
Support - trade name per MOS:COMMONNAME Dede2008 (talk) 08:23, 11 May 2021 (UTC)[reply]
support Common name and easy to understand Jaswinder1122 (talk) 11:12, 11 May 2021 (UTC)[reply]
Support renaming to Covaxin based on the widespread adoption by various sources. --Fernando Trebien (talk) 17:12, 13 May 2021 (UTC)[reply]
Support renaming to Covaxin: It is known under that name here in Paraguay where I live, and have received it this morning. No-one knows BBV152 here. (Paraguay being one of the few countries in South America that has authorised its use) Renaud OLGIATI (talk) 19:59, 13 May 2021 (UTC)[reply]
Support renaming to Covaxin: It is widely known under the name Covaxin here in India. No one actually knows what BBV152 is. Also the brand name COVAXIN® is registered by the company Bharat Biotech responsible for its development and manufacturing in India. (talk) 09:14, 14 May 2021 (UTC)[reply]
Support almost entirely known as Covaxin only. extra999 (talk) 13:28, 14 May 2021 (UTC)[reply]

The discussion above is closed. Please do not modify it. Subsequent comments should be made on the appropriate discussion page. No further edits should be made to this discussion.

A Commons file used on this page or its Wikidata item has been nominated for deletion[edit]

The following Wikimedia Commons file used on this page or its Wikidata item has been nominated for deletion:

Covaxin vial.jpg

Participate in the deletion discussion at the nomination page. —Community Tech bot (talk) 07:02, 30 June 2021 (UTC)[reply]

Semi-protected edit request on 16 July 2021[edit]

This edit request has been answered. Set the |answered= or |ans= parameter to no to reactivate your request.

‹ The template Edit semi-protected is being considered for merging. ›

The efficacy section is unclear, as it does not clearly specify the overall efficacy of the vaccine.

Please add to the section:

The overall efficacy of Covaxin in 77.8%.

Sources: https://timesofindia.indiatimes.com/india/covaxins-overall-efficacy-77-8-65-2-effective-against-delta-variant-bharat-biotech/articleshow/84087789.cms https://www.gavi.org/vaccineswork/indias-covaxin-vaccine-shows-high-efficacy-against-covid-19-infections-phase-3 Dhruv Malik (talk) 08:07, 16 July 2021 (UTC)[reply]

Comment: User:Dhruv Malik, We need to present all the cases. See for example (https://en.wikipedia.org/wiki/Oxford–AstraZeneca_COVID-19_vaccine#Effectiveness). Thus, its correctly represented and requires no change. 2402:3A80:6E3:2F77:7193:D3BB:C7EC:25DE (talk) 18:33, 21 July 2021 (UTC)[reply]

This is a 2-dose vaccine. Dosing interval is... how many weeks?[edit]

It should be mentioned in quite beginning of this article that this is a 2-dose vaccine.

--ee1518 (talk) 16:38, 4 September 2021 (UTC)[reply]

Semi-protected edit request on 12 November 2021[edit]

This edit request has been answered. Set the |answered= or |ans= parameter to no to reactivate your request.

‹ The template Edit semi-protected is being considered for merging. ›

Please replace the phase-III preprint reference with this peer reviewed article^[1] at the Covaxin#Efficacy and Covaxin#Phase_III_trials sections.

References

^ Ella, Raches; Reddy, Siddarth; Blackwelder, William; Potdar, Varsha; Yadav, Pragya; Sarangi, Vamshi; Aileni, Vinay K; Kanungo, Suman; Rai, Sanjay; Reddy, Prabhakar; Verma, Savita; Singh, Chandramani; Redkar, Sagar; Mohapatra, Satyajit; Pandey, Anil; Ranganadin, Pajanivel; Gumashta, Raghavendra; Multani, Manish; Mohammad, Shameem; Bhatt, Parul; Kumari, Laxmi; Sapkal, Gajanan; Gupta, Nivedita; Abraham, Priya; Panda, Samiran; Prasad, Sai; Bhargava, Balram; Ella, Krishna; Vadrevu, Krishna Mohan (November 2021). "Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial". The Lancet: S0140673621020006. doi:10.1016/S0140-6736(21)02000-6.

2402:3A80:6CF:BBB9:CD3F:2714:94D5:8EC5 (talk) 10:36, 12 November 2021 (UTC)[reply]

Done Abrilando232 (talk) 04:54, 13 November 2021 (UTC)[reply]

9165090187[edit]

9165090187 — Preceding unsigned comment added by 2409:4043:4C81:3D22:7021:FEB3:28BD:F663 (talk) 13:35, 22 February 2022 (UTC)[reply]

[1] Ella, Raches; Reddy, Siddarth; Blackwelder, William; Potdar, Varsha; Yadav, Pragya; Sarangi, Vamshi; Aileni, Vinay K; Kanungo, Suman; Rai, Sanjay; Reddy, Prabhakar; Verma, Savita; Singh, Chandramani; Redkar, Sagar; Mohapatra, Satyajit; Pandey, Anil; Ranganadin, Pajanivel; Gumashta, Raghavendra; Multani, Manish; Mohammad, Shameem; Bhatt, Parul; Kumari, Laxmi; Sapkal, Gajanan; Gupta, Nivedita; Abraham, Priya; Panda, Samiran; Prasad, Sai; Bhargava, Balram; Ella, Krishna; Vadrevu, Krishna Mohan (November 2021). "Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial". The Lancet: S0140673621020006. doi:10.1016/S0140-6736(21)02000-6.

[1]